{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["auto-antibodies", "autoimmunity", "cannabidiol", "cannabis", "cannabis derivatives", "terpenes", "tetrahydrocannabinol"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34322454", "DateRevised": {"Year": "2024", "Month": "04", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "07", "Day": "21"}], "Language": ["eng"], "ELocationID": ["10.2147/ITT.S267905"], "Journal": {"ISSN": "2253-1556", "JournalIssue": {"Volume": "10", "PubDate": {"Year": "2021"}}, "Title": "ImmunoTargets and therapy", "ISOAbbreviation": "Immunotargets Ther"}, "ArticleTitle": "Cannabis and Autoimmunity: Possible Mechanisms of Action.", "Pagination": {"StartPage": "261", "EndPage": "271", "MedlinePgn": "261-271"}, "Abstract": {"AbstractText": ["Medical cannabis (MC) describes the usually inhaled or ingested use of a cannabis plant or cannabis extract for medicinal purposes. The action of whole cannabis plants is extremely complex because their large number of active compounds not only bind to a plethora of different receptors but also interact with each other both synergistically and otherwise. Renewed interest in the medicinal properties of cannabis has led to increasing research into the practical uses of cannabis derivatives, and it has been found that the endocannabinoid system (particularly CB2 receptor activation) is a possible target for the treatment of inflammatory and the autoimmune diseases related to immune cell activation. However, in vivo findings still lack, creating difficulties in applying translational cannabinoid research to human immune functions. In this review, we summarized the main mechanisms of action of medical cannabis plant especially regarding the immune system and the endocannabinoid system, looking at preliminary clinical data in three most important autoimmune diseases of three different specialities: rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease."], "CopyrightInformation": "\u00a9 2021 Giorgi et al."}, "AuthorList": [{"Identifier": ["0000-0003-0369-1700"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Rheumatology Unit, Internal Medicine Department, ASST Fatebenefratelli-Sacco, Milan University School of Medicine, Milan, Italy."}], "LastName": "Giorgi", "ForeName": "Valeria", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Rheumatology Unit, ATS Sardegna, P. Dettori Hospital, Tempio Pausania, Italy."}], "LastName": "Marotto", "ForeName": "Daniela", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Rheumatology Unit, Internal Medicine Department, ASST Settelaghi, Ospedale Di Circolo - Fondazione Macchi, Varese, Italy."}], "LastName": "Batticciotto", "ForeName": "Alberto", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy."}], "LastName": "Atzeni", "ForeName": "Fabiola", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Rheumatology Unit, Internal Medicine Department, ASST Fatebenefratelli-Sacco, Milan University School of Medicine, Milan, Italy."}], "LastName": "Bongiovanni", "ForeName": "Sara", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Rheumatology Unit, Internal Medicine Department, ASST Fatebenefratelli-Sacco, Milan University School of Medicine, Milan, Italy."}], "LastName": "Sarzi-Puttini", "ForeName": "Piercarlo", "Initials": "P"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Immunotargets Ther", "NlmUniqueID": "101606565", "ISSNLinking": "2253-1556"}, "CoiStatement": "All of the authors declare that they have no conflict of interest in relation to this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bonini SA, Premoli M, Tambaro S, et al. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227:300\u2013315. doi:10.1016/j.jep.2018.09.004", "ArticleIdList": ["10.1016/j.jep.2018.09.004", "30205181"]}, {"Citation": "Touw M. The religious and medicinal uses of cannabis in China, India and Tibet. J Psychoactive Drugs. 1981;13:23\u201334. doi:10.1080/02791072.1981.10471447", "ArticleIdList": ["10.1080/02791072.1981.10471447", "7024492"]}, {"Citation": "Chopra IC, Chopra RN. The use of the cannabis drugs in India. Bull Narc. 1957;9:4\u201329."}, {"Citation": "Hall W. The Indian Hemp Drugs Commission 1893-1894. Addiction. 2019;114(9):1679\u20131682.", "ArticleIdList": ["31788878"]}, {"Citation": "Hanu\u0161 LO, Meyer SM, Mu\u00f1oz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33:1357\u20131392. doi:10.1039/C6NP00074F", "ArticleIdList": ["10.1039/C6NP00074F", "27722705"]}, {"Citation": "Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of Hashish. J Am Chem Soc. 1964;86:1646\u20131647. doi:10.1021/ja01062a046", "ArticleIdList": ["10.1021/ja01062a046"]}, {"Citation": "Russell C, Rueda S, Room R, Tyndall M, Fischer B. Routes of administration for cannabis use - basic prevalence and related health outcomes: a scoping review and synthesis. Int J Drug Policy. 2018;52:87\u201396. doi:10.1016/j.drugpo.2017.11.008", "ArticleIdList": ["10.1016/j.drugpo.2017.11.008", "29277082"]}, {"Citation": "Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359:1\u201318. doi:10.1016/S0014-2999(98)00649-9", "ArticleIdList": ["10.1016/S0014-2999(98)00649-9", "9831287"]}, {"Citation": "Cabral GA, Rogers TJ, Lichtman AH. Turning over a new leaf: cannabinoid and endocannabinoid modulation of immune function. J Neuroimmune Pharmacol. 2015;10:193\u2013203. doi:10.1007/s11481-015-9615-z", "ArticleIdList": ["10.1007/s11481-015-9615-z", "PMC4469415", "26054900"]}, {"Citation": "Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147:S163\u2013S171. doi:10.1038/sj.bjp.0706406", "ArticleIdList": ["10.1038/sj.bjp.0706406", "PMC1760722", "16402100"]}, {"Citation": "Zgair A, Lee JB, Wong JCM, et al. Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep. 2017;7:1\u201312. doi:10.1038/s41598-017-15026-z", "ArticleIdList": ["10.1038/s41598-017-15026-z", "PMC5674070", "29109461"]}, {"Citation": "Gould J. 4 Big questions. Nature. 2015;527:4. doi:10.1038/nj7577-265a", "ArticleIdList": ["10.1038/nj7577-265a", "26565047"]}, {"Citation": "Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178:1669\u20131678. doi:10.1503/cmaj.071178", "ArticleIdList": ["10.1503/cmaj.071178", "PMC2413308", "18559804"]}, {"Citation": "Fitzcharles MA, Baerwald C, Ablin J, H\u00e4user W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016;30:47\u201361. doi:10.1007/s00482-015-0084-3", "ArticleIdList": ["10.1007/s00482-015-0084-3", "26767993"]}, {"Citation": "Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a Systematic Review and Meta- Analysis of Randomized Controlled Trials. Pain Physician. 2017;6:E755\u2013E796. doi:10.36076/ppj.20.5.E755", "ArticleIdList": ["10.36076/ppj.20.5.E755", "28934780"]}, {"Citation": "Maccallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12\u201319. doi:10.1016/j.ejim.2018.01.004", "ArticleIdList": ["10.1016/j.ejim.2018.01.004", "29307505"]}, {"Citation": "Ryberg E, Larsson N, Sj\u00f6gren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092\u20131101. doi:10.1038/sj.bjp.0707460", "ArticleIdList": ["10.1038/sj.bjp.0707460", "PMC2095107", "17876302"]}, {"Citation": "Almogi-Hazan O, Or R. Cannabis, the endocannabinoid system and immunity\u2014the journey from the bedside to the bench and back. Int J Mol Sci. 2020;21:1\u201317. doi:10.3390/ijms21124448", "ArticleIdList": ["10.3390/ijms21124448", "PMC7352399", "32585801"]}, {"Citation": "Capasso R, Borrelli F, Aviello G, et al. Cannabidiol, extracted from cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154:1001\u20131008. doi:10.1038/bjp.2008.177", "ArticleIdList": ["10.1038/bjp.2008.177", "PMC2451037", "18469842"]}, {"Citation": "Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem. 2008;104:1091\u20131100. doi:10.1111/j.1471-4159.2007.05073.x", "ArticleIdList": ["10.1111/j.1471-4159.2007.05073.x", "18028339"]}, {"Citation": "Ol\u00e1h A, Szekanecz Z, B\u00edr\u00f3 T. Targeting cannabinoid signaling in the immune system: \u201cHigh\u201d-ly exciting questions, possibilities, and challenges. Front Immunol. 2017;8:1. doi:10.3389/fimmu.2017.01487", "ArticleIdList": ["10.3389/fimmu.2017.01487", "PMC5686045", "29176975"]}, {"Citation": "Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946\u20131949. doi:10.1126/science.1470919", "ArticleIdList": ["10.1126/science.1470919", "1470919"]}, {"Citation": "Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89\u201397.", "ArticleIdList": ["7575630"]}, {"Citation": "Laezza C, Pagano C, Navarra G, et al. The endocannabinoid system: a target for cancer treatment. Int J Mol Sci. 2020;21. doi:10.3390/ijms21030747", "ArticleIdList": ["10.3390/ijms21030747", "PMC7037210", "31979368"]}, {"Citation": "Perisetti A, Rimu AH, Khan SA, Bansal P, Goyal H. Role of cannabis in inflammatory bowel diseases. Ann Gastroenterol. 2020;33:134\u2013144. doi:10.20524/aog.2020.0452", "ArticleIdList": ["10.20524/aog.2020.0452", "PMC7049239", "32127734"]}, {"Citation": "Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc B Biol Sci. 2012;367:3216\u20133228.", "ArticleIdList": ["PMC3481524", "23108541"]}, {"Citation": "Jourdan T, Djaouti L, Demizieux L, Gresti J, Verg\u00e8s B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes. 2010;59:926\u2013934. doi:10.2337/db09-1482", "ArticleIdList": ["10.2337/db09-1482", "PMC2844840", "20110567"]}, {"Citation": "Busquets Garcia A, Soria-Gomez E, Bellocchio L, Marsicano G. Cannabinoid receptor type-1: breaking the dogmas. F1000Research. 2016;5:1\u20139. doi:10.12688/f1000research.8245.1", "ArticleIdList": ["10.12688/f1000research.8245.1", "PMC4879932", "27239293"]}, {"Citation": "Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61\u201365. doi:10.1038/365061a0", "ArticleIdList": ["10.1038/365061a0", "7689702"]}, {"Citation": "Kinsey SG, Mahadevan A, Zhao B, et al. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology. 2011;60:244\u2013251. doi:10.1016/j.neuropharm.2010.09.004", "ArticleIdList": ["10.1016/j.neuropharm.2010.09.004", "PMC3021987", "20849866"]}, {"Citation": "N\u00fa\u00f1ez E, Benito C, Pazos MR, et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse. 2004;53:208\u2013213.", "ArticleIdList": ["15266552"]}, {"Citation": "Gali\u00e8gue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54\u201361. doi:10.1111/j.1432-1033.1995.tb20780.x", "ArticleIdList": ["10.1111/j.1432-1033.1995.tb20780.x", "7556170"]}, {"Citation": "Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. 1999;65:637\u2013644. doi:10.1016/S0024-3205(99)00286-6", "ArticleIdList": ["10.1016/S0024-3205(99)00286-6", "10462064"]}, {"Citation": "Kaplan BLF, Springs AEB, Kaminski NE. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol. 2008;76:726\u2013737. doi:10.1016/j.bcp.2008.06.022", "ArticleIdList": ["10.1016/j.bcp.2008.06.022", "PMC2748879", "18656454"]}, {"Citation": "Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016;96:1593\u20131659. doi:10.1152/physrev.00002.2016", "ArticleIdList": ["10.1152/physrev.00002.2016", "27630175"]}, {"Citation": "Sharma CV, Long JH, Shah S, et al. First evidence of the conversion of paracetamol to AM404 in human cerebrospinal fluid. J Pain Res. 2017;10:2703\u20132709. doi:10.2147/JPR.S143500", "ArticleIdList": ["10.2147/JPR.S143500", "PMC5716395", "29238213"]}, {"Citation": "Pertwee RG. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: \u0394 9-tetrahydrocannabinol, cannabidiol and \u0394 9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199\u2013215. doi:10.1038/sj.bjp.0707442", "ArticleIdList": ["10.1038/sj.bjp.0707442", "PMC2219532", "17828291"]}, {"Citation": "Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133\u2013150. doi:10.1016/j.pharmthera.2017.02.041", "ArticleIdList": ["10.1016/j.pharmthera.2017.02.041", "28232276"]}, {"Citation": "Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172:4790\u20134805. doi:10.1111/bph.13250", "ArticleIdList": ["10.1111/bph.13250", "PMC4621983", "26218440"]}, {"Citation": "Morgan CJA, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry. 2010;197:285\u2013290. doi:10.1192/bjp.bp.110.077503", "ArticleIdList": ["10.1192/bjp.bp.110.077503", "20884951"]}, {"Citation": "Woelfl T, Rohleder C, Mueller JK, et al. Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion, cognition, and attention: a Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. Front Psychiatry. 2020;11. doi:10.3389/fpsyt.2020.576877", "ArticleIdList": ["10.3389/fpsyt.2020.576877", "PMC7693539", "33304282"]}, {"Citation": "Russo EB, Marcu J. Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol. 2017;80:67\u2013134.", "ArticleIdList": ["28826544"]}, {"Citation": "Gon\u00e7alves ECD, Baldasso GM, Bicca MA, Paes RS, Capasso R, Dutra RC. Terpenoids, cannabimimetic ligands, beyond the cannabis plant. Molecules. 2020;25:1567. doi:10.3390/molecules25071567", "ArticleIdList": ["10.3390/molecules25071567", "PMC7181184", "32235333"]}, {"Citation": "Mammana S, Cavalli E, Gugliandolo A, et al. Could the combination of two non-psychotropic cannabinoids counteract neuroinflammation? Effectiveness of cannabidiol associated with cannabigerol. Med. 2019;55. doi:10.3390/medicina55110747", "ArticleIdList": ["10.3390/medicina55110747", "PMC6915685", "31752240"]}, {"Citation": "Udoh M, Santiago M, Devenish S, McGregor IS, Connor M. Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol. 2019;176:4537\u20134547. doi:10.1111/bph.14815", "ArticleIdList": ["10.1111/bph.14815", "PMC6932936", "31368508"]}, {"Citation": "Bento AF, Marcon R, Dutra RC, et al. \u03b2-caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPAR\u03b3 pathway. Am J Pathol. 2011;178:1153\u20131166. doi:10.1016/j.ajpath.2010.11.052", "ArticleIdList": ["10.1016/j.ajpath.2010.11.052", "PMC3070571", "21356367"]}, {"Citation": "de Almeida AAC, Silva RO, Nicolau LAD, et al. Physio-pharmacological investigations about the anti-inflammatory and antinociceptive efficacy of (+)-limonene epoxide. Inflammation. 2017;40:511\u2013522. doi:10.1007/s10753-016-0496-y", "ArticleIdList": ["10.1007/s10753-016-0496-y", "28091830"]}, {"Citation": "Ramalho TR, Filgueiras LR, De Oliveira MTP, et al. Gamma-Terpinene modulation of LPS-stimulated macrophages is dependent on the PGE2/IL-10 Axis. Planta Med. 2016;82:1341\u20131345. doi:10.1055/s-0042-107799", "ArticleIdList": ["10.1055/s-0042-107799", "27224271"]}, {"Citation": "Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74:129\u2013180. doi:10.1016/S0163-7258(97)82001-3", "ArticleIdList": ["10.1016/S0163-7258(97)82001-3", "9336020"]}, {"Citation": "Vaughan CW, Christie MJ. Retrograde signalling by endocannabinoids. Handb Exp Pharmacol. 2005;(168):367\u201383. doi:10.1007/3-540-26573-2_12", "ArticleIdList": ["10.1007/3-540-26573-2_12", "16596781"]}, {"Citation": "Pisanu A, Acquas E, Fenu S, Di Chiara G. Modulation of \u03949-THC-induced increase of cortical and hippocampal acetylcholine release by \u03bc opioid and D1 dopamine receptors. Neuropharmacology. 2006;50:661\u2013670. doi:10.1016/j.neuropharm.2005.11.023", "ArticleIdList": ["10.1016/j.neuropharm.2005.11.023", "16427098"]}, {"Citation": "Pistis M, Ferraro L, Pira L, et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002;948:155\u2013158. doi:10.1016/S0006-8993(02)03055-X", "ArticleIdList": ["10.1016/S0006-8993(02)03055-X", "12383968"]}, {"Citation": "Vrechi TA, Crunfli F, Costa AP, Torr\u00e3o AS. Cannabinoid receptor Type 1 agonist ACEA protects neurons from death and attenuates endoplasmic reticulum stress-related apoptotic pathway signaling. Neurotox Res. 2018;33:846\u2013855. doi:10.1007/s12640-017-9839-1", "ArticleIdList": ["10.1007/s12640-017-9839-1", "29134561"]}, {"Citation": "Xu C, Hermes DJ, Nwanguma B, et al. Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein. Mol Cell Neurosci. 2017;83:92\u2013102. doi:10.1016/j.mcn.2017.07.003", "ArticleIdList": ["10.1016/j.mcn.2017.07.003", "PMC5587778", "28733129"]}, {"Citation": "Saliba SW, Marcotegui AR, Fortw\u00e4ngler E, et al. Correction: AM404, paracetamol metabolite, prevents prostaglandin synthesis in activated microglia by inhibiting COX activity. J Neuroinflammation. 2018;15:34. doi:10.1186/s12974-018-1072-1", "ArticleIdList": ["10.1186/s12974-018-1072-1", "PMC5801836", "29409515"]}, {"Citation": "Lowin T, Apitz M, Anders S, Straub RH. Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner. Arthritis Res Ther. 2015;17. doi:10.1186/s13075-015-0845-5", "ArticleIdList": ["10.1186/s13075-015-0845-5", "PMC4644337", "26567045"]}, {"Citation": "Watzl B, Scuderi P, Watson RR. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13:1091\u20131097. doi:10.1016/0192-0561(91)90160-9", "ArticleIdList": ["10.1016/0192-0561(91)90160-9", "1667651"]}, {"Citation": "Watzl B, Scuderi P, Watson RR. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol. 1991:63\u201370.", "ArticleIdList": ["1659139"]}, {"Citation": "Nichols JM, Kaplan BLF. Immune responses regulated by cannabidiol. Cannabis Cannabinoid Res. 2020;5:12\u201331. doi:10.1089/can.2018.0073", "ArticleIdList": ["10.1089/can.2018.0073", "PMC7173676", "32322673"]}, {"Citation": "Wu HY, Chang AC, Wang CC, et al. Cannabidiol induced a contrasting pro-apoptotic effect between freshly isolated and precultured human monocytes. Toxicol Appl Pharmacol. 2010;246:141\u2013147. doi:10.1016/j.taap.2010.05.003", "ArticleIdList": ["10.1016/j.taap.2010.05.003", "20471992"]}, {"Citation": "Jenny M, Santer E, Pirich E, Schennach H, Fuchs D. \u03949-Tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro. J Neuroimmunol. 2009;207:75\u201382. doi:10.1016/j.jneuroim.2008.12.004", "ArticleIdList": ["10.1016/j.jneuroim.2008.12.004", "19167098"]}, {"Citation": "Kozela E, Lev N, Kaushansky N, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. 2011;163:1507\u20131519. doi:10.1111/j.1476-5381.2011.01379.x", "ArticleIdList": ["10.1111/j.1476-5381.2011.01379.x", "PMC3165959", "21449980"]}, {"Citation": "Jan TR, Kaminski NE. Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J Leukoc Biol. 2001;69:841\u2013849.", "ArticleIdList": ["11358994"]}, {"Citation": "Chen W, Kaplan BLF, Pike ST, et al. Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIV gp120. J Leukoc Biol. 2012;92:1093\u20131102. doi:10.1189/jlb.0212082", "ArticleIdList": ["10.1189/jlb.0212082", "PMC3476243", "22899554"]}, {"Citation": "Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204\u2013e1211. doi:10.1212/WNL.0000000000005254", "ArticleIdList": ["10.1212/WNL.0000000000005254", "PMC5890607", "29540584"]}, {"Citation": "Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS. Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.01782", "ArticleIdList": ["10.3389/fimmu.2018.01782", "PMC6085417", "30123217"]}, {"Citation": "Selvi E, Lorenzini S, Garcia-Gonzalez E, et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol. 2008;26:574\u2013581.", "ArticleIdList": ["18799087"]}, {"Citation": "Kinsey SG, Naidu PS, Cravatt BF, Dudley DT, Lichtman AH. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol Biochem Behav. 2011;99:718\u2013725. doi:10.1016/j.pbb.2011.06.022", "ArticleIdList": ["10.1016/j.pbb.2011.06.022", "PMC3164582", "21740924"]}, {"Citation": "Gentili M, Ronchetti S, Ricci E, et al. Selective CB2 inverse agonist JTE907 drives T cell differentiation towards a Treg cell phenotype and ameliorates inflammation in a mouse model of inflammatory bowel disease. Pharmacol Res. 2019;141:21\u201331. doi:10.1016/j.phrs.2018.12.005", "ArticleIdList": ["10.1016/j.phrs.2018.12.005", "30552973"]}, {"Citation": "Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97:9561\u20139566. doi:10.1073/pnas.160105897", "ArticleIdList": ["10.1073/pnas.160105897", "PMC16904", "10920191"]}, {"Citation": "Shapiro CM, Orlina AR, Unger P, Billings AA. Antibody response to cannabis. JAMA. 1974;230:81\u201382. doi:10.1001/jama.1974.03240010049030", "ArticleIdList": ["10.1001/jama.1974.03240010049030", "4547141"]}, {"Citation": "McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB 2. Mol Pharmacol. 2008;73:441\u2013450. doi:10.1124/mol.107.041863", "ArticleIdList": ["10.1124/mol.107.041863", "17965195"]}, {"Citation": "Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003;23:1398\u20131405. doi:10.1523/JNEUROSCI.23-04-01398.2003", "ArticleIdList": ["10.1523/JNEUROSCI.23-04-01398.2003", "PMC6742252", "12598628"]}, {"Citation": "Giudice ED, Rinaldi L, Passarotto M, et al. Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. J Leukoc Biol. 2007;81:1512\u20131522. doi:10.1189/jlb.1206738", "ArticleIdList": ["10.1189/jlb.1206738", "17339608"]}, {"Citation": "Cassol OJ Jr, Comim CM, Silva BR, et al. Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res. 2010;1348:128\u2013138. doi:10.1016/j.brainres.2010.06.023", "ArticleIdList": ["10.1016/j.brainres.2010.06.023", "20561509"]}, {"Citation": "El-Gohary M, Eid MA. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol. 2004;23:149\u2013156. doi:10.1191/0960327104ht426oa", "ArticleIdList": ["10.1191/0960327104ht426oa", "15119535"]}, {"Citation": "Jan TR, Su ST, Wu HY, Liao MH. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. Int Immunopharmacol. 2007;7:773\u2013780. doi:10.1016/j.intimp.2007.01.015", "ArticleIdList": ["10.1016/j.intimp.2007.01.015", "17466911"]}, {"Citation": "Dotsey E, Ushach I, Pone E, et al. Transient cannabinoid receptor 2 blockade during immunization heightens intensity and breadth of antigen-specific antibody responses in young and aged mice. Sci Rep. 2017;7. doi:10.1038/srep42584", "ArticleIdList": ["10.1038/srep42584", "PMC5314369", "28209996"]}, {"Citation": "Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007;13:492\u2013497. doi:10.1038/nm1561", "ArticleIdList": ["10.1038/nm1561", "17401376"]}, {"Citation": "Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology. 2010;215:598\u2013605. doi:10.1016/j.imbio.2009.04.001", "ArticleIdList": ["10.1016/j.imbio.2009.04.001", "PMC3005548", "19457575"]}, {"Citation": "Schwarz H, Blanco FJ, Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol. 1994;55:107\u2013115. doi:10.1016/0165-5728(94)90152-X", "ArticleIdList": ["10.1016/0165-5728(94)90152-X", "7962480"]}, {"Citation": "Chiurchi\u00f9 V, Lanuti M, Catanzaro G, Fezza F, Rapino C, Maccarrone M. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis. 2014;233:55\u201363. doi:10.1016/j.atherosclerosis.2013.12.042", "ArticleIdList": ["10.1016/j.atherosclerosis.2013.12.042", "24529123"]}, {"Citation": "Staiano RI, Loffredo S, Borriello F, et al. Human lung-resident macrophages express CB 1 and CB 2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. J Leukoc Biol. 2016;99:531\u2013540. doi:10.1189/jlb.3HI1214-584R", "ArticleIdList": ["10.1189/jlb.3HI1214-584R", "PMC4787289", "26467187"]}, {"Citation": "Lee WS, Erdelyi K, Matyas C, et al. Cannabidiol limits T cell\u2013mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Mol Med. 2016;22:136\u2013146. doi:10.2119/molmed.2016.00007", "ArticleIdList": ["10.2119/molmed.2016.00007", "PMC5004721", "26772776"]}, {"Citation": "Persidsky Y, Fan S, Dykstra H, Reichenbach NL, Rom S, Ramirez SH. Activation of cannabinoid type two receptors (CB2) diminish inflammatory responses in macrophages and brain endothelium. J Neuroimmune Pharmacol. 2015;10:302\u2013308. doi:10.1007/s11481-015-9591-3", "ArticleIdList": ["10.1007/s11481-015-9591-3", "PMC4795159", "25666933"]}, {"Citation": "Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J Biochem. 2004;135:517\u2013524. doi:10.1093/jb/mvh063", "ArticleIdList": ["10.1093/jb/mvh063", "15115777"]}, {"Citation": "Roth MD, Castaneda JT, Kiertscher SM. Exposure to \u03949-tetrahydrocannabinol impairs the differentiation of human monocyte-derived dendritic cells and their capacity for T cell activation. J Neuroimmune Pharmacol. 2015;10:333\u2013343. doi:10.1007/s11481-015-9587-z", "ArticleIdList": ["10.1007/s11481-015-9587-z", "PMC4470806", "25614186"]}, {"Citation": "Kapellos TS, Taylor L, Feuerborn A, et al. Cannabinoid receptor 2 deficiency exacerbates inflammation and neutrophil recruitment. FASEB J. 2019;33:6154\u20136167. doi:10.1096/fj.201802524R", "ArticleIdList": ["10.1096/fj.201802524R", "PMC6629158", "30799631"]}, {"Citation": "Adhikary S, Kocieda VP, Yen JH, Tuma RF, Ganea D. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood. 2012;120:3741\u20133749. doi:10.1182/blood-2012-06-435362", "ArticleIdList": ["10.1182/blood-2012-06-435362", "PMC3488886", "22972984"]}, {"Citation": "Nam G, Jeong SK, Park BM, et al. Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model. Ann Dermatol. 2016;28:22\u201329. doi:10.5021/ad.2016.28.1.22", "ArticleIdList": ["10.5021/ad.2016.28.1.22", "PMC4737832", "26848215"]}, {"Citation": "Hegde VL, Singh UP, Nagarkatti PS, Nagarkatti M. Critical role of mast cells and peroxisome proliferator\u2013activated receptor \u03b3 in the induction of myeloid-derived suppressor cells by marijuana cannabidiol in vivo. J Immunol. 2015;194:5211\u20135222. doi:10.4049/jimmunol.1401844", "ArticleIdList": ["10.4049/jimmunol.1401844", "PMC4433789", "25917103"]}, {"Citation": "Robinson RH, Meissler JJ, Fan X, Yu D, Adler MW, Eisenstein TK. A CB2-selective cannabinoid suppresses T-cell activities and increases Tregs and IL-10. J Neuroimmune Pharmacol. 2015;10(2):318\u2013332. doi:10.1007/s11481-015-9611-3", "ArticleIdList": ["10.1007/s11481-015-9611-3", "PMC4528965", "25980325"]}, {"Citation": "Stebulis JA, Johnson DR, Rossetti RG, Burstein SH, Zurier RB. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008;83:666\u2013670. doi:10.1016/j.lfs.2008.09.004", "ArticleIdList": ["10.1016/j.lfs.2008.09.004", "18840450"]}, {"Citation": "Peyravian N, Deo S, Daunert S, Jimenez JJ. Cannabidiol as a novel therapeutic for immune modulation. ImmunoTargets Ther. 2020;9:131\u2013140. doi:10.2147/ITT.S263690", "ArticleIdList": ["10.2147/ITT.S263690", "PMC7445536", "32903924"]}, {"Citation": "Correa F, Mestre L, Docagne F, Guaza C. Activation of cannabinoid CB 2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol. 2005;145:441\u2013448. doi:10.1038/sj.bjp.0706215", "ArticleIdList": ["10.1038/sj.bjp.0706215", "PMC1576166", "15821753"]}, {"Citation": "Abo-Elnazar S, Moaaz M, Ghoneim H, Molokhia T, El-Korany W. Th17/Treg imbalance in opioids and cannabinoids addiction: relationship to NF-\u03baB activation in CD4+ T cells. Egypt J Immunol. 2014;21:33\u201347.", "ArticleIdList": ["25812351"]}, {"Citation": "Castillo PE, Younts TJ, Ch\u00e1vez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76:70\u201381. doi:10.1016/j.neuron.2012.09.020", "ArticleIdList": ["10.1016/j.neuron.2012.09.020", "PMC3517813", "23040807"]}, {"Citation": "B\u00f6rner C, Smida M, H\u00f6llt V, Schraven B, Kraus J. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem. 2009;284:35450\u201335460. doi:10.1074/jbc.M109.006338", "ArticleIdList": ["10.1074/jbc.M109.006338", "PMC2790974", "19858202"]}, {"Citation": "Katz-Talmor D, Katz I, Porat-Katz BS, Shoenfeld Y. Cannabinoids for the treatment of rheumatic diseases \u2014 where do we stand? Nat Rev Rheumatol. 2018;14:488\u2013498. doi:10.1038/s41584-018-0025-5", "ArticleIdList": ["10.1038/s41584-018-0025-5", "29884803"]}, {"Citation": "Molina PE, Amedee AM, Winsauer P, Nelson S, Bagby G, Simon L. Behavioral, metabolic, and immune consequences of chronic alcohol or cannabinoids on HIV/AIDs: studies in the non-human primate SIV model. J Neuroimmune Pharmacol. 2015;10:217\u2013232. doi:10.1007/s11481-015-9599-8", "ArticleIdList": ["10.1007/s11481-015-9599-8", "PMC4470723", "25795088"]}, {"Citation": "Da silva T, Hafizi S, Watts JJ, et al. In vivo imaging of translocator protein in long-term cannabis users. JAMA Psychiatry. 2019;76:1305\u20131313. doi:10.1001/jamapsychiatry.2019.2516", "ArticleIdList": ["10.1001/jamapsychiatry.2019.2516", "PMC6751758", "31532458"]}, {"Citation": "Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17:623\u2013639.", "ArticleIdList": ["30116049"]}, {"Citation": "\u015aledzi\u0144ski P, Nowak-Terpi\u0142owska A, Zeyland J. Cannabinoids in medicine: cancer, immunity, and microbial diseases. Int J Mol Sci. 2021;22:1\u201322.", "ArticleIdList": ["PMC7795897", "33383838"]}, {"Citation": "Sarzi-Puttini P, Batticciotto A, Atzeni F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? Expert Rev Clin Immunol. 2019;15:1019\u20131032. doi:10.1080/1744666X.2019.1665997", "ArticleIdList": ["10.1080/1744666X.2019.1665997", "31512536"]}, {"Citation": "Fitzcharles M-A, Ste-Marie PA, Clauw DJ, et al. Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskelet Disord. 2014;15:258. doi:10.1186/1471-2474-15-258", "ArticleIdList": ["10.1186/1471-2474-15-258", "PMC4121007", "25080153"]}, {"Citation": "Richardson D, Pearson RG, Kurian N, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10:R43. doi:10.1186/ar2401", "ArticleIdList": ["10.1186/ar2401", "PMC2453762", "18416822"]}, {"Citation": "Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 2020;11:1\u201311. doi:10.1038/s41419-020-02892-1", "ArticleIdList": ["10.1038/s41419-020-02892-1", "PMC7463000", "32873774"]}, {"Citation": "Atzeni F, Nucera V, Masala IF, Sarzi-Puttini P, Bonitta G. Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. Pharmacol Res. 2019;149:104402. doi:10.1016/j.phrs.2019.104402", "ArticleIdList": ["10.1016/j.phrs.2019.104402", "31536783"]}, {"Citation": "Fonseca JE, Santos MJ, Canh\u00e3o H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8:538\u2013542. doi:10.1016/j.autrev.2009.01.012", "ArticleIdList": ["10.1016/j.autrev.2009.01.012", "19189867"]}, {"Citation": "Gui H, Liu X, Liu LR, Su DF, Dai SM. Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis. Immunobiology. 2015;220:817\u2013822. doi:10.1016/j.imbio.2014.12.012", "ArticleIdList": ["10.1016/j.imbio.2014.12.012", "25601571"]}, {"Citation": "Kotschenreuther K, Waqu\u00e9 I, Yan S, et al. Cannabinoids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases. Cell Mol Immunol. 2021;18:764\u2013766. doi:10.1038/s41423-020-0437-4", "ArticleIdList": ["10.1038/s41423-020-0437-4", "PMC8027621", "32346098"]}, {"Citation": "Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles MA, Marotto D, H\u00e4user W. Cannabinoids in the treatment of rheumatic diseases: pros and cons. Autoimmun Rev. 2019;18:102409. doi:10.1016/j.autrev.2019.102409", "ArticleIdList": ["10.1016/j.autrev.2019.102409", "31648042"]}, {"Citation": "Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006;45:50\u201352. doi:10.1093/rheumatology/kei183", "ArticleIdList": ["10.1093/rheumatology/kei183", "16282192"]}, {"Citation": "Webb M, Luo L, Ma JY, Tham CS. Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. Neurosci Lett. 2008;439:106\u2013110. doi:10.1016/j.neulet.2008.04.090", "ArticleIdList": ["10.1016/j.neulet.2008.04.090", "18501510"]}, {"Citation": "Wen J, Ribeiro R, Tanaka M, Zhang Y. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis. Neuropharmacology. 2015;99:196\u2013209. doi:10.1016/j.neuropharm.2015.07.010", "ArticleIdList": ["10.1016/j.neuropharm.2015.07.010", "26189763"]}, {"Citation": "De Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fern\u00e1ndez-Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology. 2012;62:2299\u20132308. doi:10.1016/j.neuropharm.2012.01.030", "ArticleIdList": ["10.1016/j.neuropharm.2012.01.030", "22342378"]}, {"Citation": "Paolicelli D, Direnzo V, Manni A, et al. Long-term data of efficacy, safety, and tolerability in a real-life setting of THC/CBD oromucosal spray-treated multiple sclerosis patients. J Clin Pharmacol. 2016;56:845\u2013851. doi:10.1002/jcph.670", "ArticleIdList": ["10.1002/jcph.670", "26608223"]}, {"Citation": "Celius EG, Vila C. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity. Brain Behav. 2018;8(5):e00962. doi:10.1002/brb3.962", "ArticleIdList": ["10.1002/brb3.962", "PMC5943754", "29761015"]}, {"Citation": "Zettl UK, Rommer P, Hipp P, Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord. 2016;9:9\u201330. doi:10.1177/1756285615612659", "ArticleIdList": ["10.1177/1756285615612659", "PMC4710104", "26788128"]}, {"Citation": "Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. 2007;152:649\u2013654. doi:10.1038/sj.bjp.0707458", "ArticleIdList": ["10.1038/sj.bjp.0707458", "PMC2190016", "17891167"]}, {"Citation": "Pesce M, D\u2019Alessandro A, Borrelli O, et al. Endocannabinoid-related compounds in gastrointestinal diseases. J Cell Mol Med. 2018;22:706\u2013715. doi:10.1111/jcmm.13359", "ArticleIdList": ["10.1111/jcmm.13359", "PMC5783846", "28990365"]}, {"Citation": "Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678\u20131685. doi:10.1002/ibd.20960", "ArticleIdList": ["10.1002/ibd.20960", "PMC5531765", "19408320"]}, {"Citation": "Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113:1202\u20131209. doi:10.1172/JCI200419465", "ArticleIdList": ["10.1172/JCI200419465", "PMC385396", "15085199"]}, {"Citation": "D\u2019Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 2006;20:568\u2013570. doi:10.1096/fj.05-4943fje", "ArticleIdList": ["10.1096/fj.05-4943fje", "16403786"]}, {"Citation": "Sa\u0142aga M, Mokrowiecka A, Zakrzewski PK, et al. Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J Crohns Colitis. 2014;8:998\u20131009. doi:10.1016/j.crohns.2014.01.025", "ArticleIdList": ["10.1016/j.crohns.2014.01.025", "PMC4136976", "24530133"]}, {"Citation": "Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J. 2011;25:2711\u20132721. doi:10.1096/fj.10-176602", "ArticleIdList": ["10.1096/fj.10-176602", "21551239"]}, {"Citation": "Engel MA, Kellermann CA, Burnat G, Hahn EG, Rau T, Konturek PC. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid [TNBS]-induced colitis. J Physiol Pharmacol. 2010;61:89\u201397.", "ArticleIdList": ["20228420"]}, {"Citation": "Marqu\u00e9z L, Su\u00e1rez J, Iglesias M, Bermudez-Silva FJ, Rodr\u00edguez de Fonseca F, Andreu M. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One. 2009;4:e6893. doi:10.1371/journal.pone.0006893", "ArticleIdList": ["10.1371/journal.pone.0006893", "PMC2731878", "19730730"]}, {"Citation": "Duncan M, Mouihate A, Mackie K, et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol. 2008;295:G78\u2013G87. doi:10.1152/ajpgi.90285.2008", "ArticleIdList": ["10.1152/ajpgi.90285.2008", "PMC2494728", "18483180"]}, {"Citation": "Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O\u2019Sullivan SE. Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo-a Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019;25:1006\u20131018. doi:10.1093/ibd/izz017", "ArticleIdList": ["10.1093/ibd/izz017", "31054246"]}, {"Citation": "Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891\u2013896. doi:10.1097/MEG.0b013e328349bb4c", "ArticleIdList": ["10.1097/MEG.0b013e328349bb4c", "21795981"]}, {"Citation": "Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2014;20:472\u2013480. doi:10.1097/01.MIB.0000440982.79036.d6", "ArticleIdList": ["10.1097/01.MIB.0000440982.79036.d6", "24407485"]}, {"Citation": "Allegretti JR, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809\u20132814. doi:10.1097/01.MIB.0000435851.94391.37", "ArticleIdList": ["10.1097/01.MIB.0000435851.94391.37", "PMC4126607", "24185313"]}, {"Citation": "Mbachi C, Attar B, Oyenubi O, et al. Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: a propensity matched retrospective cohort study. Med (United States). 2019;98. doi:10.1097/MD.0000000000016551", "ArticleIdList": ["10.1097/MD.0000000000016551", "PMC6708902", "31393356"]}, {"Citation": "Benson MJ, Abelev SV, Connor SJ, et al. Medicinal cannabis for inflammatory bowel disease: a survey of perspectives, experiences, and current use in Australian patients. Crohns Colitis. 2020;2:1\u201315.", "ArticleIdList": ["PMC9802391", "36777301"]}, {"Citation": "Naftali T, Lev LB, Yablekovitz D, Half E, Konikoff FM. Treatment of Crohn\u2019s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455\u2013458.", "ArticleIdList": ["21910367"]}, {"Citation": "Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn\u2019s disease, a Randomized Controlled Trial. Dig Dis Sci. 2017;62:1615\u20131620. doi:10.1007/s10620-017-4540-z", "ArticleIdList": ["10.1007/s10620-017-4540-z", "28349233"]}, {"Citation": "Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with crohn\u2019s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276\u20131280.e1. doi:10.1016/j.cgh.2013.04.034", "ArticleIdList": ["10.1016/j.cgh.2013.04.034", "23648372"]}, {"Citation": "Irving PM, Iqbal T, Nwokolo C, et al. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflamm Bowel Dis. 2018;24:714\u2013724. doi:10.1093/ibd/izy002", "ArticleIdList": ["10.1093/ibd/izy002", "29538683"]}, {"Citation": "Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Lish I, Konikoff FM, Ringel Y. Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol. 2019;31:1376\u20131381. doi:10.1097/MEG.0000000000001565", "ArticleIdList": ["10.1097/MEG.0000000000001565", "31567639"]}, {"Citation": "Giorgi V, Bongiovanni S, Atzeni F, Marotto D, Salaffi F, Sarzi-Puttini P. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. Clin Exp Rheumatol. 2020;38:53\u201359.", "ArticleIdList": ["32116208"]}, {"Citation": "Katz D, Katz I, Porat-Katz BS, Shoenfeld Y. Medical cannabis: another piece in the mosaic of autoimmunity? Clin Pharmacol Ther. 2017;101:230\u2013238. doi:10.1002/cpt.568", "ArticleIdList": ["10.1002/cpt.568", "27859024"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "2", "Day": "26"}, {"Year": "2021", "Month": "6", "Day": "25"}, {"Year": "2021", "Month": "7", "Day": "29", "Hour": "6", "Minute": "52"}, {"Year": "2021", "Month": "7", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "30", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "7", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["34322454", "PMC8313508", "10.2147/ITT.S267905", "267905"]}}], "PubmedBookArticle": []}